The Future of Psychedelic Medicines with Mindset Pharma

There’s been much excitement in the psychedelic industry this year – with great progress in drug development and the passing of agreeable legislation. So, if the impact of legislation is an indicator of public sentiment, one can conclude that psychedelic medicine has become a bipartisan issue. We sat down with James Lanthier, CEO of Mindset Pharma to discuss these developments and Mindset Pharma’s unique approach to psychedelic drug development.

Last week, Mindset announced that they’ve entered into an exclusive sales agreement with PhamAla Biotech Holdings Inc. (CSE: MDMA). Under the agreement, PharmAla will be the exclusive global reseller of Mindset’s cGMP (i.e., pharmaceutical grade) psilocybin to appropriately licensed clinical researchers.

Mindset has recently completed production of a large batch of cGMP psilocybin at the U.S. site of an international contract development and manufacturing company (CDMO) pursuant to the annual DEA quota on psilocybin.

0 0 votes
Article Rating

Mindset Pharma is a market awareness client of Capital 10X.

The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Capital 10X hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.

Notify of

Inline Feedbacks
View all comments